Literature DB >> 20863157

Early [¹⁸F]fluorodeoxyglucose positron emission tomography-based response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: a children's oncology group report.

Peter D Cole1, Kathleen M McCarten, Richard A Drachtman, Pedro de Alarcon, Lu Chen, Tanya M Trippett, Cindy L Schwartz.   

Abstract

The International Harmonization Project defined complete response (CR) after treatment for Hodgkin disease (HD) by absence of fluorodeoxyglucose avidity, regardless of the size of residual masses. Residual avidity after initial treatment is known to predict inferior survival. In the setting of retrieval therapy, early positron emission tomography (PET) scans may improve assessment of treatment efficacy. Retrospective analysis after 2 cycles of gemcitabine and vinorelbine for refractory HD revealed 6 CR among 13 patients by PET and 1 CR in 13 by computed tomography (CT). No relationship between PET response and event-free or overall survival could be discerned, presumably because of the heterogeneity of subsequent therapies.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20863157      PMCID： PMC3083978          DOI： 10.3109/08880018.2010.504250

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN： 0888-0018            Impact factor:   1.969


  11 in total

1.  High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.

Authors:  Julye C Lavoie; Joseph M Connors; Gordon L Phillips; Donna E Reece; Michael J Barnett; Donna L Forrest; Randy D Gascoyne; Donna E Hogge; Stephen H Nantel; John D Shepherd; Clayton A Smith; Kevin W Song; Heather J Sutherland; Cynthia L Toze; Nicholas J S Voss; Thomas J Nevill
Journal:  Blood       Date:  2005-05-03       Impact factor: 22.113

Review 2.  Autologous transplantation in relapsed and refractory Hodgkin's disease.

Authors:  Andreas Josting
Journal:  Eur J Haematol Suppl       Date:  2005-07

3.  MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease.

Authors:  F B Hagemeister; N Tannir; P McLaughlin; P Salvador; S Riggs; W S Velasquez; F Cabanillas
Journal:  J Clin Oncol       Date:  1987-04       Impact factor: 44.544

4.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

5.  Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

Authors:  Malik E Juweid; Sigrid Stroobants; Otto S Hoekstra; Felix M Mottaghy; Markus Dietlein; Ali Guermazi; Gregory A Wiseman; Lale Kostakoglu; Klemens Scheidhauer; Andreas Buck; Ralph Naumann; Karoline Spaepen; Rodney J Hicks; Wolfgang A Weber; Sven N Reske; Markus Schwaiger; Lawrence H Schwartz; Josee M Zijlstra; Barry A Siegel; Bruce D Cheson
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

6.  Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients.

Authors:  P L Zinzani; M Tani; S Fanti; L Alinari; G Musuraca; E Marchi; V Stefoni; P Castellucci; M Fina; M Farshad; S Pileri; M Baccarani
Journal:  Ann Oncol       Date:  2006-06-09       Impact factor: 32.976

7.  The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.

Authors:  Andrea Gallamini; Luigi Rigacci; Francesco Merli; Luca Nassi; Alberto Bosi; Isabella Capodanno; Stefano Luminari; Umberto Vitolo; Rosaria Sancetta; Emilio Iannitto; Livio Trentin; Caterina Stelitano; Silvia Tavera; Alberto Biggi; Antonio Castagnoli; Annibale Versari; Michele Gregianin; Ettore Pelosi; Pierfederico Torchio; Alessandro Levis
Journal:  Haematologica       Date:  2006-04       Impact factor: 9.941

8.  Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report.

Authors:  Peter D Cole; Cindy L Schwartz; Richard A Drachtman; Pedro A de Alarcon; Lu Chen; Tanya M Trippett
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

9.  New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.

Authors:  Bruce D Cheson
Journal:  Radiol Clin North Am       Date:  2008-03       Impact factor: 2.303

10.  High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices.

Authors:  YeeYie E Lieskovsky; Sarah S Donaldson; Mylin A Torres; Ruby M Wong; Michael D Amylon; Michael P Link; Rajni Agarwal
Journal:  J Clin Oncol       Date:  2004-11-15       Impact factor: 44.544
View more
  1 in total

1.  Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.

Authors:  Peter D Cole; Kathleen M McCarten; Qinglin Pei; Menachem Spira; Monika L Metzger; Richard A Drachtman; Terzah M Horton; Rizvan Bush; Susan M Blaney; Brenda J Weigel; Kara M Kelly
Journal:  Lancet Oncol       Date:  2018-08-16       Impact factor: 41.316
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.